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Lithium has been the treatment of choice for patients with bipolar disorder (BD) for nearly
70 years. It is recommended by all relevant guidelines as a first-line treatment for
maintenance therapy. In this review, we outline the current state of evidence for lithium
in the treatment of BD over the lifespan. First, we summarize the evidence on efficacy in
general, from relapse prevention to acute anti-manic treatment and its role in treating
mood episodes with mixed features and bipolar depression. As patients are often treated
for many years and different aspects have to be considered in different phases of life, we
discuss the particularities of lithium in the treatment of paediatric BD, in older aged
individuals and in pregnant women. Lastly, we discuss the evidence on lithium's proposed
suicide-preventive effects, the dangers of rapid discontinuation and lithium's adverse
effects, particularly with regard to long-term treatment.
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Bipolar disorder (BD) is an episodic illness with a very heterogeneous clinical course. It usually
presents as a severe, chronic, and disabling condition characterized by mood alterations between
euthymia, major depression, and (hypo-)mania. The estimated lifetime prevalence ranges from
0.6% to 2.4% worldwide (1, 2). BD is usually a lifelong disease, hence requiring lifelong treatment
strategies. One of the major pharmacological agents in the treatment of BD is lithium. It remains the
gold standard in preventing recurrences in BD I (mania and depressive episodes) and BD II
(hypomania and depressive episodes) and is effective in the treatment of mania. Additionally, the
proposed anti-suicide effect of lithium is unique and potentially of high relevance in the treatment of
BD over the lifespan, as patients with BD suffer from high suicide rates (3). Over the last decades,
other substances such as second generation antipsychotics (SGA) and anticonvulsants have been
prescribed more frequently and there has been a tendency to avoid lithium in the treatment of BD.
Reasons may be the overestimation of potential side effects as compared to other substances by
professionals and patients alike, despite the highly problematic metabolic profile of antipsychotics
(e.g., Olanzapine), particularly over the lifespan (4).
This narrative review focuses on lithium-treatment over the lifespan in BD and gives a summary
of its effectiveness, side effects, and treatment recommendations with regard to specific treatment
conditions and subtypes of BD. Furthermore, we discuss the risk of lithium-discontinuation, which
is an important topic in the treatment of BD over the lifespan.g May 2020 | Volume 11 | Article 3771
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The pharmacological treatment of BD has several goals. Lithium
is the agent of the “first hour” in the treatment of BD and has
been used over decades in all phases of the disease. Lithium
treatment aims at the prevention of relapses and is used in the
treatment of acute episodes, such as mania, depression, and
specific subtypes, such as mood episodes with mixed features or
rapid cycling (RC) (see below). Especially with regard to the
lifespan, the efficacy of lithium in special treatment conditions,
such as BD in paediatric and older aged patients and BD during
pregnancy and postpartum are of high relevance. For each of
these conditions, different recommendations are available from
different treatment guidelines (5). The German S3 guidelines also
recommends lithium as the first choice of treatment for patients
with high risk for suicidality (6). First, we give a short summary
of the general effects of lithium in mania, depression, and
maintenance treatment of BD.
Lithium in Maintenance Treatment
Preventing new episodes in BD is essential with regard to quality
of life, participation in society and preventing long-term
disability. Lithium remains the gold standard in achieving this
goal. It is effective in both type I and type II BD (e.g., (5)). Only
for lithium, randomized controlled trials (RCTs) without an
“enriched design”, favoring the substance to be investigated,
have been performed (7, 8). Several meta-analyses of
randomized placebo-controlled, long-term trials could verify
that lithium significantly reduces the risk of new episodes
(mania and depression) compared to placebo (e.g., (9–12)). A
Cochrane review found the risk of any relapse to be 36% for
lithium and 61% for Placebo over the course of 1 year,
corresponding to an absolute risk reduction of 25% [NNT = 4,
(13)]. Kessing et al. as well as Hayes et al. found lithium
monotherapy to be superior to monotherapy with other
maintenance mood stabilizers in real life conditions (14, 15).
This is reflected by its status as the first-line drug in many
international guidelines (5). For optimal efficacy in long-term
treatment of BD, target serum levels should generally be around
0.6–0.8 mmol/L, while specific treatment situations and patients
may require slightly higher or lower lithium levels (16).
Lithium in Treatment of Mania
While manic episodes are often the most impressive part of BD,
their duration is usually shorter compared to that of other disease
phases in both BD-I and BD-II. A number of pharmacological
agents have been investigated and have proven their efficacy in
the treatment of mania, including lithium (17). The network
meta-analysis by Cipriani et al. found an effect size of 0.40 SMD,
indicating a moderately sized effect, which is comparable to other
anti-manic agents (18). For example, lithium showed a
comparable efficacy to quetiapine in a 12-week RCT (19).
Despite its proven anti-manic properties, lithium has lost some
of its relevance in the treatment of mania in the recent years,
partly due to the large number of SGAs that have been licensed
for this indication. Reasons for favoring SGAs over lithiumFrontiers in Psychiatry | www.frontiersin.org 2include the shorter time of dosage increase and sedation, a
common side effect of SGAs that is often welcomed during
manic agitation. Further potential disadvantages of lithium
include the small therapeutic window and hence the necessity
for repeated serum level controls (20). In addition, no parenteral
application is available for lithium. Notwithstanding these
limitations, lithium should be considered as a first-line therapy
for manic episodes, as long-term phase-prophylactic treatment is
almost always required afterward, for which lithium is
considered the first choice. In the treatment of manic episodes,
higher levels of 0.8 to 1.2 mmol/L are required in order to achieve
optimal response.Lithium in Treatment of Bipolar
Depression
Bipolar depression is the predominant pole in BD type I and type
II and responsible for a large number of suicides. The suicide rate
is 20-times above that of the general-population (21), which is
considerably larger than that of unipolar depression (22). Bipolar
depression is also associated with a high rate of morbidity and
mortality due to comorbid somatic disorders (23). However,
treatment of bipolar depression is challenging for clinicians, as
the classical treatment strategies of unipolar depression
(antidepressants, lithium) show small(er), if any, effects (24).
The lack of effectiveness of antidepressants in BD has been the
topic of an ongoing controversy (25, 26). There is evidence that
antidepressants may worsen the course of the disease in patients
with mixed symptoms or RC by increasing the switch risk or
causing tachyphylaxis after repeated antidepressant drug
exposures (27).
Similarly, the available data strongly doubt the effectiveness of
lithium in treating bipolar depression. The large EMBOLDEN I
study found that lithium was not more effective than placebo in
treating bipolar depression (28). In an open-label RCT
comparing venlafaxine and lithium in bipolar depression in
BD type II, lithium was significantly less effective than the
antidepressant (29). However, relatively low lithium serum
levels are a possible limitation of this and several other trials
investigating lithium in the treatment of bipolar depression.
Albeit the lack of evidence supporting lithium monotherapy in
the treatment of bipolar depression, there are substantial
differences in international treatment guidelines with regard to
the role of lithium in bipolar depression (30). Some guidelines,
such as the CANMAT guidelines (31), still regard lithium as a
first line treatment option in bipolar depression. These guidelines
argue that lithium should be considered in the acute treatment of
bipolar depression due to its central role as a mood stabilizer, its
effectiveness in preventing mania and the proposed anti-suicide
effect. These guidelines highlight the low number of studies
investigating lithium in bipolar depression and the limitations
of these studies. Contrarily, the German S3 guideline does not
recommend the use of lithium monotherapy in the treatment of
bipolar depression (6). The WFSBP guideline agrees with that
recommendation and emphasizes the combination therapy of
lithium with other agents in bipolar depression (32).May 2020 | Volume 11 | Article 377
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FEATURES AND RAPID CYCLING
BD, especially in the lifelong course, is typically characterized by
recurring mood episodes of opposite polarity. However, patients
may also experience episodes in which depressive and manic
symptoms co-occur. These phases were traditionally called
mixed states or mixed episodes. The DSM-5 substituted these
terms by the so-called “mixed specifier”, which indicates the
presence of mixed symptoms in either (hypo-)manic or
depressive episodes (33). Patients with mixed features in the
course of their illness have a considerably higher risk to commit
suicide and higher rates of (psychiatric) comorbidities (e.g.,
anxiety disorders, substance dependence and personality
disorders). They suffer from high rates of relapses and
experience a larger number of new episodes compared to BD
patients without mixed symptoms (34).
Treatment of patients suffering from affective episodes with
mixed features is particularly demanding for clinicians, especially
as there is a lack of RCTs investigating these patients. The
available data on the effectiveness of lithium in mood episodes
with mixed symptoms are inconclusive (33, 35). In patients with
a manic episode and additional depressive symptoms, lithium
was found to be less effective than valproate (36).
Studies investigating the effectiveness of lithium in the
maintenance therapy found it to be less effective in patients
with mixed symptoms than in patients with “pure” mania.
However, episodes with mixed features may generally be more
difficult to treat than classic episodes. A post hoc analysis of
lithium in “dysphoric mania” even found lithium not to be more
effective than placebo (37). However, there are several
shortcomings of all of these studies, for example the post-doc
design and limitations with regard to the patient population.
Given the high rates of suicidality during episodes with mixed
symptoms and the anti-suicide properties of lithium, it should
not be ignored as a pharmacological treatment-option in these
patients. However, (more) positive data (mainly based on post
hoc analyses) are available for SGAs and valproate in the
treatment of BD with mixed features.
Another clinical phenotype of BD is the concept of RC. RC is
defined as a course of BD that includes at least four distinct mood
episodes (including major depressive, manic, hypomanic, with or
without mixed features) occurring within a 12-month period. RC
has a lifetime prevalence of 5 to 33% among BD patients, which
emphasizes its clinical relevance (38, 39). Patients with RC suffer
from a higher burden of symptoms, higher rates of suicide
attempts and completed suicides and they are frequently
suffering from other psychiatric comorbidities over the lifespan
of BD (40, 41). Patients with RC show a prolonged and complex
course of their disease and high rates of treatment failure
compared to patients without RC (42). Risk factors that are
associated with the onset of RC are female gender,
hypothyroidism, and antidepressant medication (43).
Only very little data on the treatment of RC are available from
randomized clinical trials. Naturalistic and non-controlled
studies suggest that lithium is less effective in patients with RCFrontiers in Psychiatry | www.frontiersin.org 3than in those without (44). However, all available treatments
show lower effectiveness in patients with RC and lithium may
show better efficacy than other mood stabilizers except for
valproate (45). In a re-analysis of patients with BP II receiving
venlafaxine and lithium, however, there were no differences in
response or relapse rates between patients with or without RC
(46). In a study from Suppes et al., no differences could be found
between lithium and lamotrigine in reducing depressive
symptoms in patients with bipolar depression and RC (47).
Regarding long-term treatment of BD and RC, lithium has
been investigated in a prospective trial (cross-over design,
duration of 2 years) in comparison to carbamazepine or the
combination of both (48). Lithium monotherapy was inferior to
the combination therapy in patients with a history of RC, while
there was no difference to carbamazepine monotherapy. In
addition, lithium monotherapy was equally effective in
comparison to a combination treatment of lithium and
valproate in RC (relapse rates) and in comparison to valproate
monotherapy (49).LITHIUM IN PAEDIATRIC BIPOLAR
DISORDERS
BD often begins in adolescence (50) and usually requires lifelong
treatment including pharmacotherapy and psychosocial
interventions (51). It is important to distinguish between
paediatric and adult BD when choosing the appropriate
medication, as side effects may affect patients of different age
groups differentially.
Lithium has been approved for the acute and maintenance
treatment of mixed and manic episodes of BD I in children and
adolescents (age from 7 to 17 years) by the FDA. The
effectiveness of lithium in paediatric patients has been
demonstrated by numerous studies [e.g., (52, 53)].
In young patients with BD, the risks and benefits of
pharmacological (long-term) treatment have to be balanced
even more carefully, as the longer duration of exposure to the
medication poses particular risks of adverse events. Before
starting lithium treatment, standard examinations such as
baseline laboratory checks of thyroid hormones, creatinine,
blood salts, and calcium levels should be performed. The
monitoring of lithium-levels and of other blood parameters is
comparable to that of adults. As in all BD patients but especially
in paediatric BD, the spectrum of lithium adverse effects should
be thoroughly discussed, especially with regard to lithium
intoxication. In adolescents, adequate hydration during the
summer and during high levels of physical activity are
important concerns the patient should be informed of. Cases
of significant dehydration (such as due to emesis or diarrhoea)
can make a dose reduction or pausing of the medication
necessary. Like in adults, thyroid hormone status has to be
closely monitored, as lithium may lead to hypothyroidism
requiring the substitution of thyroid hormones (54). In
paediatric BD, acute and long-term treatment with lithium
seems to have relatively little effect on body weight (53, 55)May 2020 | Volume 11 | Article 377
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unfavorable metabolic profile. Serious side effects of lithium in
paediatric BD, which have been reported and therefore must be
recognized, are suicidal ideation, change of blood cell count, and
neurological side effects (54).
Dosing Strategies in Paediatric BD
The elimination half-time of lithium is significantly shorter and
the clearance of lithium significantly higher in paediatric
patients. Therefore, Landersdorfer et al. (56) recommend a
twice-daily dosing of lithium to achieve acceptable blood
concentrations. Data are missing for once-daily dosing of
lithium in paediatric BD and is thus not recommended.
To summarize, lithium is an effective treatment strategy in the
treatment of paediatric BD in different phases of the disease, in
mixed and manic episodes and in the maintenance phase.LITHIUM USE IN PREGNANT AND
POSTPARTUM WOMEN WITH BD
Women with BD are at an elevated risk of recurrence during the
peripartum and postpartum period with relapse rates as high as
40–70% (57, 58). Recent research suggests that lithium
discontinuation may be responsible for the elevated relapse
risk during pregnancy, as pregnancy itself only has a small or
even no effect on relapse rates in BD (57, 59). A majority of
pregnant women with BD decide to self-discontinue lithium or
even have problems getting a prescription for lithium (60, 61).
There is a high variability in the available information and
recommendations regarding lithium treatment during
pregnancy (62). While lithium is the most recommended agent
in BD during pregnancy, there is a lack of high-quality data.
Observational studies support the use of lithium in the
postpartum period in relapse prevention (58). However, the
benefits of relapse prevention have to be weighed against
potential adverse effects on mother and child (63).
One major fear is the assumed teratogenicity of lithium during
pregnancy, especially the risk of Ebstein's anomaly. In one of the
largest cohort studies, Paterno et al. found that lithium intake
during the first trimester is associated with an increased risk of
cardiac malformations. In this study the adjusted risk ratio for
cardiac malformations between exposed and non-exposed infants
was 1.65 (95% confidence interval [CI], 1.02 to 2.68) and it showed
a dose-dependent relationship. Nevertheless, the effect size was
lower than previously assumed, with an absolute risk increase of
1.25% (64). In a meta-analysis byMunk-Olsen (65), lithium intake
during pregnancy did not correlate with complications during
pregnancy or delivery. However, the authors reported an increased
risk for “cardiovascular defects, neural tube defects, hypospadias,
and epispadias (OR 1.71), but not for major cardiac malformations
(e.g., Ebstein's anomaly)”. For a detailed overview, we recommend
the review of Hermann et al. (62).
Several experts recommend continuing lithium in patients
with BD I who have been stable on lithium to prevent relapse or
even mood instability. Nonetheless, a critical discussion shouldFrontiers in Psychiatry | www.frontiersin.org 4be held with the patient that involves the risks, benefits, and
alternatives for treatment during pregnancy and postpartum.
Changing of medication during pregnancy and postpartum
should be avoided when possible (62). Patients continuing
taking lithium should take a reduced dosage or even stop
taking lithium in the critical period of heart development (4 to
12 weeks). However, lithium should never be discontinued
abruptly. An increase in the GFR and an expansion of the
blood volume occurring during pregnancy can cause a decrease
in lithium levels during the first and second trimesters (66).
Therefore, the lithium dosage may have to be increased in order
to ensure sufficient lithium levels (67). Most guidelines propose
to check lithium levels every 2 to 4 weeks, for the last trimester a
weekly check is recommended (63, 66, 68, 69). Further
monitoring is needed if patients develop preeclampsia,
hyperemesis gravidarum, or suffer from fever. During the first
trimester and concurrent lithium treatment, foetal ultrasound
should be performed to check for cardiac malformations (63,
70, 71).
Lithium and Breastfeeding
There is a controversial debate on whether or not lithium should
be continued during breastfeeding, since studies investigating its
effects on the child are scarce (70). As there is an increased
chance of a recurrence of BD with lithium discontinuation in
general (57) and during the postpartum period in particular, a
change of treatment regimen for breastfeeding is not the first
choice. In support of this, Bergink (72) could verify that patients
with a new episode of BD during postpartum taking lithium had
fewer recurrences after 9-month postpartum compared to
patients receiving an antipsychotic treatment. Most of the
guidelines conclude with a negative benefit-risk ratio for
breastfeeding during lithium treatment (63, 70).LITHIUM IN OLDER AGE BIPOLAR
DISORDER
Patients aged 60 years and older account for a quarter of all BD
patients (73). Nonetheless, pharmacological and non-
pharmacological treatment strategies in these individuals are
hardly studied in RCTs (74). BD patients in older age have a
significantly reduced life expectancy of up to 15 to 20 years. They
are at a higher risk of suffering from metabolic syndrome,
cardiovascular diseases, general renal diseases and cognitive
decline (75–77) compared to the general population. The lower
life expectancy means that older patients may be exposed to
prophylactic medication for a shorter period of time than
younger patients, potentially translating to a reduced risk of long-
term side effects (e.g., with regard to kidney function). Based on the
available data, there are treatment recommendations for BD in older
age in international treatment guidelines (31).
Lithium is considered the first line medication in older aged
patients with BD in the maintenance treatment. It is
recommended for the prevention of depression and mania
given the evidence from adult studies, but also because theMay 2020 | Volume 11 | Article 377
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geriatric patients (73). However, due to concerns regarding
tolerability and adverse events, lithium is prescribed less
frequently in older individuals, although it is usually well
tolerated by most of these patients (78, 79).
The randomized controlled GERI−BD trial investigated the
efficacy and tolerability of lithium and divalproex in the
treatment of mania in older age (60 years and above). Target
serum concentrations were 0.80–0.99 mEq/L for lithium and 80–
99 mm/L for valproate.
In this trial, lithium and valproic acid demonstrated to be
equally effective in the 3-week follow-up (74) but lithium was
more effective in reducing manic symptoms after the 9-week
follow-up (74). Lithium and valproate showed a comparable
frequency of side effects and were generally tolerated, providing
evidence for lithium and valproate to be relatively safe with few
adverse effects in BD in older adults.
Special Considerations for Using Lithium
in Older Age
It is recommended that therapeutic lithium levels should be
lower in patients with BD and older age (31, 80, 81). Dehydration
is common in older patients and should be prevented,
particularly if lithium is prescribed. Special attention should be
paid, if other substances are prescribed that carry a risk of
increasing lithium blood levels. Medications that should be
prescribed carefully under these circumstances are diuretics,
angiotensin-converting enzyme (ACE) inhibitors, angiotensin
receptor blockers (ARBs), but also non-steroidal anti-
inflammatory drugs (NSAIDs). Lithium blood levels and renal
parameters should be checked regularly, especially at the
beginning of the treatment (82, 83).
The recommended lithium levels in BD patients in older age
are 0.4–0.8 mmol/L (31). For depressive episodes and
maintenance therapy, serum concentrations are recommended
to be low as 0.4–0.6 mmol/L (9). The recommended serum levels
for the treatment of mania are indicated at 0.4–0.8 mmol/L for
ages 60–79 years and a bit lower (0.4–0.7 mmol/L) for patients
with the age of 80 and above (80). This is reasonable as lithium
levels higher than 0.8 mmol/L may cause neurocognitive and
neurological symptoms (84) and renal side effects (85). Long-
term treatment with lithium is associated with a reduction of the
GFR and a twofold increased risk of chronic kidney disease (86).
Patients with BD in older age are consequently at a higher risk of
these adverse effects after having taken lithium for several years
(78). Lithium levels and renal function should therefore be
controlled every 3 months in patients aged 65 and above.SIDE EFFECTS OF LITHIUM OVER
THE LIFESPAN
Lithium treatment is associated with a number of undesired side-
effects that involve different organ systems. Gastro-intestinal
complaints such as nausea, vomiting, and diarrhoea are
relatively common. Nausea affects around 10–20% of patients,Frontiers in Psychiatry | www.frontiersin.org 5particularly in the early phase of treatment and often diminishes
with longer treatment duration (87). Fine hand tremor is
reported by about 25% of patients treated with lithium (88),
the absolute risk increase was 9.6% compared to placebo in
short-term trials [NNH = 10, (89)]. Clinically, it presents as
postural tremor and its frequency and intensity correlate with
lithium serum levels (90). Management mainly includes dose
reduction. Pharmacological management with propranolol is
recommended only in cases of severe tremor, as beta-blockers
may introduce other side-effects (91).
The risk of hypothyroidism is increased 5.78-fold compared
to placebo (92) and lithium may lead to increased blood calcium
and parathyroid hormone levels (93). TSH and calcium levels
should therefore be monitored regularly; hypothyroidism can be
managed by levothyroxine substitution and is no reason for
discontinuing lithium.
Cardiological harms may also arise from lithium treatment.
In a recent review, the most common ECG abnormality was T
wave inversion. Further alterations include QT prolongation and
ventricular tachyarrhythmias (94).
Renal complications are another important concern in lithium-
treated patients. A reduced concentration ability of the kidneys is
associated with longer treatment duration (95) and is found in
54% to 73% of patients (95, 96). With lithium treatment, an excess
decline of 15% in the kidney's ability to concentrate urine is found
compared to untreated controls (92). However, as these results
stem from observational data, they have to be interpreted with
caution. A reduced concentration ability can manifest as a
nephrogenic diabetes insipidus (NDI), clinically characterized by
polyuria and polydipsia. Patients with NDI are at higher risk of
lithium intoxication and should therefore be monitored more
closely (97). Early detection is recommended and involves the
assessment of “urine volume, frequency of urination, nycturia,
thirst, and fluid intake”. Several treatment options have been
suggested with limited evidence (97). In almost all cases, NDI is
reversible when lithium is stopped.
With long-term use, lithium can cause chronic tubulo-
interstitial nephritis, which is characterized by a decrease in
the glomerular filtration rate (GFR) and may lead to chronic
kidney disease (lithium nephropathy) (97, 98). While a
detrimental effect of lithium on the kidneys seems certain, it
remains unclear to which extend the observed decline in GFR is
due to age-related renal impairment. A reduction in GFR of 0–5
ml/min is seen over 1 year and the risk of renal failure has been
estimated to be about 0.5% compared to 0.2% in controls (92). A
clinically relevant impairment of the renal function does usually
not occur before at least 15 years of lithium treatment (99). Due
to a lack of long-term studies, the evidence on lithium
nephropathy is scarce and no clear recommendations
regarding its management exist (97). If the kidney function is
impaired, reducing the dosage or stopping lithium treatment
may be necessary. Unlike NDI, renal failure may not be
reversible upon lithium discontinuation.
A potential negative effect of lithium on cognition has been
debated for many years. Typical complaints of lithium-treated
individuals involve lethargy, fatigue, lack of mental clarity, andMay 2020 | Volume 11 | Article 377
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reason for non-adherence to lithium treatment (101). While BD
is associated with cognitive dysfunctions, it remains unclear, to
which extend these arise due to the illness or the treatment. A
recent narrative review concluded that lithium may improve
some cognitive functions while deteriorating others (102).
Lithium negatively affects “immediate verbal learning and
memory (SMD 0.29, 95% CI 0.07 to 0.51), creativity (SMD
0.34, 95% CI 0.00 to 0.68) and psychomotor performance
(SMD 0.62, 95% CI 0.27 to 0.97)”, although these findings are
based on relatively few patients (103). Lithium-induced
hypothyroidism may be partly responsible for these cognitive
deficits that can thus be counter-acted by levothyroxine
substitution (104). In contrast, evidence from preclinical (105,
106) and clinical research (107) suggests that lithium may have
beneficial effects on the incidence and progression of dementia.
In support of this, a large population-based study found a
negative correlation between lithium intake and dementia
incidence (108). Patients with BD have a higher risk of
developing dementia compared to the general population and
lithium may be protective in these patients (109).These findings
are based mainly on correlational data, however, and thus need
confirmation by randomized trials.
A well-known and often unpleasant side-effect is weight gain.
It is seen more often than with placebo (OR 1.89, 95% CI 1.27 to
2.82, p=0.002). Bowden et al. reported an average increase in
body weight of 6 kg after a treatment duration of 1 year.
Interestingly, weight gain was only observed in patients that
already were obese at the beginning of the study. Among non-
obese people, no such weight gain was observed (110).
Serum levels of lithium have to be closely monitored to avoid
lithium intoxication, particularly in the elderly. Lithium
intoxication is characterized by confusion, gross tremor (as
opposed to a fine tremor as a typical side effect with
therapeutic serum levels), ataxia, falls, convulsions, and
gastrointestinal symptoms such as vomiting and diarrhoea. A
retrospective cohort study found it to occur in around 1 in 100
person-years (111). Among 1,340 patients that were followed for
17 years, no deaths due to lithium intoxication were reported.
Management includes stopping lithium, giving water (per os or
parenterally), haemodialysis, and forced diuresis (111).
There are a few contraindications that need to be considered
before initiating lithium treatment. These include cardiac pre-
conditions such as certain types of arrythmias (e.g., Brugada
syndrome), previous or current myocardial infarction and
kidney failure.LITHIUM AND SUICIDALITY
The life expectancy of patients with BD is reduced by about 10
years compared to the general population (112) and the
mortality gap seems to be increasing rather than decreasing
over the years (113). A major cause of death is suicide, which is
around 20–30-fold more frequent than in the general population
(114). Around 25–50% of patients with BD attempt suicide atFrontiers in Psychiatry | www.frontiersin.org 6some point in their life and around 15% of patients die of suicide
(115). The prevention of suicides is therefore a pivotal goal in the
treatment of BD.
Lithium has been associated with a reduced suicide risk in
patients with affective disorders including BD in a number of
studies with varying methodology (116–118). Long-term studies
suggest a strong suicide-preventing effect with suicides being
82% less frequent during lithium treatment (119). The studies
supporting this suicide-preventing effect often include
observational data, however, which are prone to bias.
Adherence to lithium treatment and lower risk for suicidal
behavior may correlate spuriously and may at least in part not
be causally related (120). Lithium treatment is likely to be
introduced when patients are at their worst, followed by a
period of improvement. The increase in suicide risk after
discontinuation of lithium treatment may be due to rebound
depression or withdrawal effects. Additionally, patients may stop
their lithium medication because their health is deteriorating,
while continuously adhering to their medication when they are
doing well.
More reliable evidence comes from RCTs. The largest meta-
analysis investigating lithium and suicidality in RCTs found a
reduction in suicides from 6/241 in the placebo group to 0/244 in
the lithium group, corresponding to an absolute risk reduction of
2.5% [NNT = 40, (3)]. Only one trial did not use a withdrawal
design, which may introduce bias due to withdrawal effects in the
placebo group. This 1-year trial reported three suicides in the
placebo arm and 0 suicides in the lithium arm, making
the estimate more uncertain (121)
A relationship between lithium concentrations in tap water
and a reduced suicide risk has even been postulated multiple
times (122), which a more recent study did not replicate (122).
The mechanism by which lithium may reduce suicides is
hypothesized to be the reduction of impulsive and aggressive
behavior in bipolar and depressed patients. By some authors, it is
thought to have a specific anti-suicide effect exceeding its mood
stabilizing properties (123).
As suicides are a special case of death, all-cause mortality
seems a more relevant outcome, unless deaths of other causes
(such as due to lithium intoxication or kidney failure) are favored
over suicides. Investigating this, Cipriani et al. included eight
RCTs with 782 patients and found a reduction in all-cause
mortality in the lithium group of 2.31% over an average of
around 81.5 weeks (Absolute risk: 5/392 (1.28%) vs. 14/392
(3.59%), absolute risk reduction: 2.31%, corresponding to an
NNT = 43). This risk reduction was rather uncertain, however,
with a wide 95% confidence interval for the odds ratio of 0.15
to 0.95.
It is possible that the mortality rate of patients treated with
lithium is not constant over time. Specifically, lithium-induced
deaths due to harms such as kidney failure may result after year-
long exposures, thereby possibly reducing the overall benefit
on mortality.
As the absolute risk reduction is rather small, it seems
uncertain, if lithium reduces overall mortality over a course of
years, which is the usual duration of treatment.May 2020 | Volume 11 | Article 377
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Psychiatric patients, including patients with BD, often stop
medication, e.g., due to concepts of their illness and treatment
that differ from those of their physicians. A lack of insight into
being ill is another reason. Furthermore, as lithium treatment is
associated with adverse effects and the long-term effects on the
body are insufficiently understood, many patients stop their
lithium medication due to unwanted effects. The most common
reasons are diarrhoea, tremor, diabetes insipidus, creatinine
increase, and weight gain (124). Furthermore, lithium
nephropathy can make discontinuation of lithium necessary.
Abrupt lithium discontinuation in patients stabilized on the
medication is associated with severe adverse effects, such as
suicidal behavior (59). In a study investigating this issue, 3 of
18 patients relapsed within 4 days after discontinuation, two of
which had been stable on lithium for as long as 42 and 58 months
(125). In a study of 64 patients with BD that were investigated in
a naturalistic setting, the relapse risk increased from 53.3% to
94.1% (NNH = 2.5) from gradual (2–4 weeks) to rapid (< 2
weeks) discontinuation over 5 years (126). Similar results were
found in a randomized trial of 161 bipolar patients. Abrupt
discontinuation (1–14 days) led to a 20-fold increase in relapse
rates as compared to gradual reduction (15–30 days) over a
course of 3 years (37% vs. 1.8%, p < 0.0001, (59)). The median
time to recurrence was decreased from 14.0 months to 2.5
months (127). The same pattern of increased relapse rates is
seen in pregnant women (128).
The risk of relapse after abrupt discontinuation seems to
exceed the risk before starting lithium treatment and may thus be
considered an iatrogenic harm (rebound phenomenon, (129). It
is therefore strongly recommended to discontinue lithium very
slowly. Whether a gradual withdrawal over more than 4 weeks is
more beneficial has not been investigated to date.
It is likely that rebound after discontinuation undermines the
validity of relapse prevention trials, in which stabilized patients
are withdrawn from lithium within a few weeks before being
randomized to placebo (129). The benefit of lithium could thus
be smaller than generally assumed.
If lithium discontinuation is followed by a relapse, patients
may want to reinstate lithium medication. Reintroduction of
lithium after discontinuation does not seem to affect treatment
efficacy (130), as had been speculated by some authors in the
past (131).Frontiers in Psychiatry | www.frontiersin.org 7CONCLUSIONS
BD is a debilitating illness with an often chronic clinical course
that usually requires lifelong treatment. Lithium has been used
for treating BD for many years since the discovery of its
antimanic properties in 1949 (132). Notwithstanding the
introduction of other therapeutic agents that have led to a
reduction in prescription of lithium in the past decades (133),
it still remains the gold standard in the treatment of BD,
particularly over the lifespan with the highest efficacy in the
maintenance treatment. The proposed suicide-preventing effect
of lithium is unique, while possibly being less substantiated than
previously thought. It is an efficacious medication in the acute
treatment of mania, while lacking efficacy in the treatment of
bipolar depression. Lithium can be used for the treatment of BD
in all age groups. It is effective in paediatric BD and can be used,
with caution, during pregnancy. Lithium use is generally not
recommended during breastfeeding, however. Older aged
patients with BD also benefit from lithium, while the serum
levels are recommended to be rather lower than in younger
adults. Lithium is generally well tolerated. However, adverse
events, such as hypothyroidism, renal dysfunctions, and
cognitive side effects have to be weighed against the benefits.
Special care is strongly recommended when discontinuing
lithium, as rapid withdrawal may lead to severe side-effects.
In sum, lithium remains an effective and generally tolerable
therapeutic agent for BD. Every clinically active psychiatrist
should be able to handle lithium comfortably, such that the
harms are minimized and the benefits outweigh the risks. We
hope that this review helps guide practitioners and patients alike.AUTHOR CONTRIBUTIONS
CV and SK drafted and wrote the manuscript. TB provided a
critical revision of the article.FUNDING
We acknowledge support from the German Research
Foundation (DFG) and the Open Access Publication Fund of
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